Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...

Saved in:

书目详细资料
Main Authors:	Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
格式:	Artigo
语言:	英语
出版:	2018
在线阅读:	https://doi.org/10.1186/s12931-018-0957-y https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
由: Marra, Alberto M., et al.
出版: (2018)

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
由: Alberto M. Marra, et al.
出版: (2015)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
由: Christina A. Eichstaedt, et al.
出版: (2022)

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
由: Hossein Ardeschir Ghofrani, et al.
出版: (2010)

Practical management of riociguat in patients with pulmonary arterial hypertension
由: Halank, Michael, et al.
出版: (2019)

Riociguat for the Treatment of Pulmonary Arterial Hypertension
由: Hossein Ardeschir Ghofrani, et al.
出版: (2013)

Pulmonary Hypertension
由: M. Hoeper, Marius, et al.
出版: (2017)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
由: Xanthouli, Panagiota, et al.
出版: (2020)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
由: Eichstaedt, Christina A., et al.
出版: (2022)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
由: Ghofrani, Hossein A, et al.
出版: (2009)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
由: Eichstaedt, Christina A., et al.
出版: (2016)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
由: Christina A. Eichstaedt, et al.
出版: (2016)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
由: Eichstaedt, Christina A., et al.
出版: (2020)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
由: Kim, Nick H, et al.
出版: (2017)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
由: Nick H. Kim, et al.
出版: (2016)

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease
由: Ghofrani, Hossein A., et al.
出版: (2015)

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study
由: Fischer, Lukas, et al.
出版: (2018)

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
由: Hossein Ardeschir Ghofrani, et al.
出版: (2013)

Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
由: Xanthouli, Panagiota, et al.
出版: (2021)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
由: Ghofrani, Hossein-Ardeschir, et al.
出版: (2020)

Effects of riociguat in severe experimental pulmonary hypertension
由: Kojonazarov, Baktybek, et al.
出版: (2011)

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension
由: Hossein Ardeschir Ghofrani, et al.
出版: (2016)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
由: Pan, Zixuan, et al.
出版: (2019)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
由: Zixuan Pan, et al.
出版: (2019)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
由: Hoeper, Marius M., et al.
出版: (2017)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
由: Marius M. Hoeper, et al.
出版: (2017)

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
由: Lewis J. Rubin, et al.
出版: (2015)

Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
由: Marius M. Hoeper, et al.
出版: (2012)

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis
由: Gerry Coghlan, et al.
出版: (2018)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
由: Harzheim, Dominik, et al.
出版: (2013)

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018
由: Ekkehard Grünig, et al.
出版: (2018)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
由: Dominik Harzheim, et al.
出版: (2013)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
由: Stephan Rosenkranz, et al.
出版: (2015)

Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study
由: G. Meyer, et al.
出版: (2021)

Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives
由: Alberto M. Marra, et al.
出版: (2014)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
由: McLaughlin, Vallerie V., et al.
出版: (2017)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
由: Vallerie V. McLaughlin, et al.
出版: (2017)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
由: Theobald, Vivienne, et al.
出版: (2022)

Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction
由: Diana Bonderman, et al.
出版: (2013)

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
由: Marius M. Hoeper, et al.
出版: (2017)